Evidence map›Paper›PMID 42164241›Full record

ArticleMolecular therapy. Advances2026

Efficacy of intranasal adenovirus vector vaccine is attenuated by type I IFN-induced NK cell activation.

Hayato Nakatani, Masashi Tachibana, Rika Onishi, Takato Nakagaki, Ken J Ishii, Kahori Shimizu, Fuminori Sakurai, Hiroyuki Mizuguchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hayato NakataniLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565-0871, Japan.
Masashi TachibanaLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565-0871, Japan.
Rika OnishiLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565-0871, Japan.
Takato NakagakiLaboratory of Biochemistry and Molecular Biology, School of Pharmaceutical Sciences, The University of Osaka, Osaka 565-0871, Japan.
Ken J IshiiDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Kahori ShimizuLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565-0871, Japan.
Fuminori SakuraiLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565-0871, Japan.
Hiroyuki MizuguchiLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenovirus vector (Adv)-based intranasal (i.n.) vaccines induce mucosal immunity and are thus a promising strategy against various infectious diseases. To improve the safety and efficacy of Adv vaccines, it is essential to clarify the mechanisms underlying the induction of immune responses. We focused on type I interferons (IFNs), which play a crucial role in the antiviral response. To elucidate the mechanisms behind i.n. Adv vaccination, we intranasally administered antigen (Ag)-expressing Adv to type I IFN receptor-deficient (

Indexed as

adenovirus vectorinnate immunitymucosal immunityNK cellstype I interferonvaccines

Identifiers

PMID42164241
PMCPMC13186022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.